Coagulation markers in diagnostic and monitoring of thromboembolic complication in COVID-19

Magdalena Czarnecka-Czapczyńska
Dorota Bartusik-Aebisher
ID
Email src
Magdalena Krupka-Olek
David Aebisher
ID
Email src
Grzegorz Cieślar
ID
Wojciech Latos
Aleksandra Kawczyk-Krupka
ID
Email src
Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland
Department of Biochemistry and General Chemistry, Medical College of the University of Rzeszow, University of Rzeszow, Rzeszow, Poland
Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland
Department of Photomedicine and Physical Chemistry, Medical College of Rzeszów University, Rzeszów, Poland
Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland
Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland
Department of Internal Medicine, Angiology and Physical Medicine, Centre for Laser Diagnostics and Therapy, Medical University of Silesia in Katowice, Bytom, Poland
Received: 1 July 2021 / Accepted: 17 July 2021 / Published: 30 September 2021

Abstract

Introduction. Coronavirus disease 2019 (COVID-19) was first observed in China in Wuhan city, Hubei province in December, 2019, and specified as a pandemic by the World Health Organization (WHO). COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2).

Aim. The aim of this article is to discuss epidemiology of thromboembolic complication in COVID-19.

Material and methods. This article is a review done in regards to discuss clinical features of the anticoagulation treatment in COVID-19.

Analysis of the literature. A review is discussed an anticoagulation treatment in 41 manuscripts.

Conclusion. Most commonly coagulation abnormalities in patient with COVID-19 is mild thrombocytopenia. Apart from their typical role in thrombosis and hemostasis, platelets mediate key aspects of immune and inflammatory.

 

Cite

Czarnecka-Czapczyńska M, Bartusik-Aebisher D, Krupka-Olek M, Aebisher D, Cieślar G, Latos W, Kawczyk-Krupka A. Coagulation markers in diagnostic and monitoring of thromboembolic complication in COVID-19. Eur J Clin Exp Med. 2021;19(3):241–245. doi: 10.15584/ejcem.2021.3.5

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited